

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In reapplication of: Fitzgerald, et al.

Group No.: 1614

SS 200 No : 00/860 668

Examiner:

Filed: 01/02/2002

JUN 1 7 2002

For: Use of Substituted 4-Biarylbutyric and 5-Biarylpentanoic Acid Derivatives as Matrix Metalloperate

Inhibitors for the Treatment of Respiratory Diseases

CERTIFICATION OF MAILING UNDER 37 C.F.R. 1.8(a)

I hereby certify that this correspondence and any papers referred to as attached are being deposited, on the date shown below, with the United States Postal Service, with sufficient postage, as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Date: JUN 1 0 2002

Muriellen Chap defaure Signature of Person Certifying

ASSISTANT COMMISSIONER FOR PATENTS WASHINGTON, D.C. 20231

TRANSMITTAL OF SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BEFORE MAILING OF FIRST OFFICE ACTION (37 C.F.R. 1.97(b))

Dear Sir:

Applicants wish to cite for the record in the above-identified application the references shown on the accompanying copy of PTO form 1449.

IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING INFORMATION DISCLOSURE STATEMENT

The information disclosure statement transmitted herewith is being filed **before** the mailing date of the first Office action on the merits.

FEE PAYMENT

Applicants believe that no fees are due with this submission. However, the Commissioner is hereby authorized to charge any fees that may have been overlooked but that are required to Deposit Account 13-3372. Additionally, please credit any overpayment to the same account.

Respectfully submitted,

Reg. No. 41,670

Telephone: (203) 812-3964

Date 1 2040

Atterney for Applicant(s)
Bayer Corporation

400 Morgan Lane

e L. Chiu

West Haven, CT 06516

- 1 -